Bergen, Norway, September 22, 2023: Lifecare AS (LIFE), a clinical stage medicalsensor company developing the next generation Continuous Glucose Monitor (CGM)announce today that additional clinical data from study LFS-SEN-001 will bepresented at the upcoming international diabetes conference hosted by theDiabetes Technology Society.
Lifecare CSO, Professor Dr. Dr. Med. Andreas Pfützner has received an invitationto present the poster "Continuous Glucose Monitoring with an Osmotic-PressureBased Continuous Glucose Sensor: Results of the First Human Pilot Study" at the annual Diabetes Technology Meeting (DTM), Tuesday November 7th, 2023.
The results from Lifecare's clinical study LFS-SEN-001 were first presented atthe American Diabetes Association Scientific Sessions (ADA) in San Diego, CA,USA, in June 2023, as a late breaking abstract. At the upcoming DTM, additionaldata will be presented.
The study data presented at the ADA included proof-of-concept in human tissue,as well as confirmation that Lifecare's CGM system Sencell has a solid clinicalaccuracy: the mean average of absolute error (MARD) value was calculated to9,6%.
In context, regulatory authorities expect a MARD below 10% to acknowledge CGMfor therapeutic (medical) decisions such as insulin dose adjustments. Incomparison, the MARD of glucose measurements in capillary blood (Blood GlucoseMonitoring - BGM), representing the gold standard for patient self-monitoring ofglucose, are in the range 5-10%.
The Sencell MARD confirms previous communication from Lifecare that the systemis at least as accurate as commercially available CGM systems. At the currentdevelopment stage, the sensor sensitivity and algorithm development provideaccuracy far better than expected.
Lifecare AS is a clinical stage medical sensor company developing technology forsensing and monitoring of various body analytes. Lifecare's main focus is tobring the next generation of Continuous Glucose Monitoring ("CGM") systems tomarket. Lifecare enables osmotic pressure as sensing principle, combined withthe ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") onthe sensor body for read-out of pressure variations. LifecareŽs sensortechnology is referred to as "Sencell" and is suitable for identifying andmonitoring the occurrence of a wide range of analytes and molecules in the humanbody.¬¬¬
For further information, please contact: Joacim Holter, CEO, Lifecare AS, firstname.lastname@example.org, +47 40 05 90 40Asle Wingsternes, Head of Communications & Public Affairs,email@example.com, +47 41 61 42 52
This information is considered to be inside information pursuant to the EUMarket Abuse Regulation and is subject to the disclosure requirements pursuantto Section 5-12 the Norwegian Securities Trading Act.